Novartis’ Exjade gets committee review
Executive Summary
Novartis' oral iron chelator Exjade (deferasirox) will be reviewed for treatment of chronic iron overload during blood transfusions by FDA's Blood Products Advisory Committee on Sept. 29. Panel will likely discuss Exjade's failure to demonstrate non-inferiority to Novartis' current iron overload therapy Desferal in the pivotal study. The meeting will be held at the CDER advisory committee conference room at 5630 Fishers Lane in Rockville, Md. beginning at 8 a.m.[Editor's note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com or call 800-627-8171.]...
You may also be interested in...
Novartis Sticks With Heart Of Pipeline: Growth Is In Cardio-Metabolic Sector
Novartis will continue to focus on the cardiovascular-metabolic segment in the near term with filings planned for new diabetes and hypertension therapies and line-extensions for its existing agents
Eisai/Biogen’s Leqembi Breezes Through Adcomm; Labeling Discussions With US FDA May Be Knottier
To get regular approval, the Alzheimer’s treatment could see tightened labeling on the need to test for ApoE ε4 status given advisory committee recommendations. Some panelists also raised concerns around use with anticoagulants and in patients with cerebral amyloid angiopathy.